Traders should monitor upcoming Phase 1 data readouts for ERAS-0015 (H1 2026) and ERAS-4001 (H2 2026) as key catalysts. The expanded China rights and strong IP protection enhance long-term optionality, but near-term valuation remains dependent on clinical execution.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $13.62entry
- T+1 · 8mo ago −0.81%α −1.83% · $13.51
- T+5 · 8mo ago +7.20%α +9.31% · $14.60
- T+20 · 7mo ago +19.75%α +16.16% · $16.31
- T+60 · 5mo ago −5.51%α −17.12% · $12.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca reported fourth quarter and full year 2025 financial results, highlighted by reduced net losses and a strong cash position bolstered by a $259 million financing in January 2026. The company emphasized early clinical progress in its RAS-targeting pipeline, including partial responses for ERAS-0015 across multiple tumor types, and expanded its licensing rights globally. Phase 1 data for ERAS-0015 and ERAS-4001 are expected in H1 and H2 2026, respectively.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year prior.
- Completed upsized public offering in January 2026, raising $258.8 million in gross proceeds, bringing pro forma cash to $434 million.
- Cash expected to fund operations into H2 2028.
- Net loss decreased to $29.1 million in Q4 2025 from $32.2 million in Q4 2024; full-year net loss improved to $124.5 million from $161.7 million in 2024.
- R&D expenses declined to $92.9 million in 2025 from $115.4 million in 2024.
- Promising early clinical activity for ERAS-0015, including confirmed partial responses in multiple RAS-mutant tumors with favorable safety and pharmacokinetics.
- Expanded ERAS-0015 licensing agreement with Joyo Pharmatech to include China, Hong Kong, and Macau, securing worldwide rights.
- U.S. composition-of-matter patents issued for ERAS-0015 (until Sept 2043) and ERAS-4001 (until June 2043).
- Phase 1 monotherapy data for ERAS-0015 expected in H1 2026; ERAS-4001 data expected in H2 2026.
Financial Impact
Reduced R&D and G&A expenses contributed to a $37.1 million improvement in net loss year-over-year; $258.8 million financing significantly strengthens near-term financial runway.
Risk Factors
- Early clinical data are preliminary and may not translate into confirmed responses or regulatory approval.
- Despite improved cash position, the company remains pre-revenue with significant future funding needs dependent on clinical progress.
- Forward-looking statements about timelines and financial runway are subject to delays and higher-than-expected costs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255076 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers